These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1808472)

  • 1. Suppression of lymphocyte signal transduction by murine mastocytoma ascites.
    Ding L; Isobe K; Yoshida T; Nakashima I
    Microbiol Immunol; 1991; 35(9):767-74. PubMed ID: 1808472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell-mediated immune responses in vitro. I. Suppression of the generation of cytotoxic lymphocytes by concanavalin A and concanavalin A-activated spleen cells.
    Peavy DL; Pierce CW
    J Exp Med; 1974 Aug; 140(2):356-69. PubMed ID: 4276949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mastocytoma-medicated suppression of mixed lymphocyte culture and mitogen responsiveness.
    DeLustro F; Argyris BF
    Cell Immunol; 1976 Jan; 21(1):177-84. PubMed ID: 129285
    [No Abstract]   [Full Text] [Related]  

  • 4. In vitro generation of tumor-specific cytotoxic lymphocytes. Secondary allogeneic mixed tumor lymphocyte culture of normal murine spleen cells.
    Gillis S; Smith KA
    J Exp Med; 1977 Aug; 146(2):468-82. PubMed ID: 69003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of humoral factors of the mastocytoma P815 cells on the formation of allospecific killers in mixed culture of lymphocytes and their cytotoxic activity].
    Medvedev AE; Dostman U; Flegel' A
    Biull Eksp Biol Med; 1989 Aug; 108(8):224-6. PubMed ID: 2529921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic T cell responses to a syngeneic tumour: conditions for primary activation in vitro.
    Warren HS; Woolnough JA; Lafferty KJ
    Aust J Exp Biol Med Sci; 1978 Apr; 56(2):247-51. PubMed ID: 98140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppressor cells in the spleen of tumor-allosensitized mice.
    Argyris BF
    Cancer Res; 1977 Sep; 37(9):3390-9. PubMed ID: 141979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmentation of B-cell responsiveness by a tumor-activated T-cell factor.
    Behforouz NC; Cerny J; Eardley DD
    Cell Immunol; 1983 Jul; 79(1):110-24. PubMed ID: 6407762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1.
    Inge TH; Hoover SK; Susskind BM; Barrett SK; Bear HD
    Cancer Res; 1992 Mar; 52(6):1386-92. PubMed ID: 1531782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell development in B cell deficient mice. III. Restriction specificity of suppressor T cell factor(s) produced in mice treated chronically with rabbit anti-mouse mu chain antibody.
    HayGlass KT; Naides SJ; Benacerraf B; Sy MS
    J Mol Cell Immunol; 1985; 2(2):107-17. PubMed ID: 2978459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens.
    Bear HD
    Cancer Res; 1986 Apr; 46(4 Pt 1):1805-12. PubMed ID: 2936451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of concanavalin A treatment on the allogeneic response of mice to challenge with P 815 mastocytoma: interleukin 2 treatment reverses concanavalin A suppression in vivo.
    Ekstedt RD; Merdian DJ
    Cell Immunol; 1984 May; 85(2):447-58. PubMed ID: 6424952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restoration of in vitro immune responsiveness of mastocytoma-suppressed splenocytes by activated T cells.
    Kamo I; Patel C; Patel N; Friedman H
    J Immunol; 1975 Aug; 115(2):382-6. PubMed ID: 807635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of cell-mediated immunity to challenge with P 815 mastocytoma in concanavalin A-treated mice.
    Ekstedt RD; Merdian DJ
    Cell Immunol; 1983 Jan; 75(1):181-7. PubMed ID: 6297806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capacity of different cell types to stimulate cytotoxic T lymphocyte precursor cells in the presence of interleukin 2.
    Dröge W; Moyers C; Wehrmaker A; Schmidt H; Panknin S; Männel D; Falk W
    J Immunol; 1984 Jun; 132(6):2749-59. PubMed ID: 6233360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic T lymphocytes reactive against a syngeneic murine tumor and their specific suppressor T cells are both elicited by in vitro allosensitization.
    Leshem B; Kedar E
    J Exp Med; 1990 Apr; 171(4):1057-71. PubMed ID: 2139097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro induction of cytotoxicity against syngeneic mastocytoma and its suppression by spleen and thymus cells from tumor-bearing mice.
    Takei F; Levy JG; Kilburn DG
    J Immunol; 1976 Feb; 116(2):288-93. PubMed ID: 814160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppression induced in vitro by mastocytoma tumor cells and cell-free extracts.
    Kamo I; Patel C; Kateley J; Friedman H
    J Immunol; 1975 Jun; 114(6):1749-56. PubMed ID: 805176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A high frequency of cytotoxic precursor cells for a syngeneic tumour.
    Warren HS; Lafferty KJ
    Scand J Immunol; 1979; 10(4):349-52. PubMed ID: 119310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of suppressor cells by syngeneic tumor transplants in mice.
    Argyris BF
    Cancer Res; 1978 May; 38(5):1269-73. PubMed ID: 147732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.